Biogen (BIIB) Change in Inventory (2009 - 2026)
Biogen (BIIB) posted quarterly Change in Inventory of -$75.7 million for Q2 2026, down 184.2% year-over-year from $89.9 million in Q2 2025, and up 34.85% quarter-over-quarter from -$116.2 million in Q1 2026.
Biogen (BIIB) Change in Inventory (2009 - 2026) Analysis & Trends
Biogen's Change in Inventory history runs 18 years deep, the most recent figure standing at -$75.7 million for Q2 2026.
- In Q2 2026, Change in Inventory fell 184.2% year-over-year to -$75.7 million; the TTM figure through Jun 2026 stood at -$155.1 million (down 236.65% YoY), while the FY2025 annual figure was $64.7 million, down 76.37% from the prior year.
- Change in Inventory for Q2 2026 stood at -$75.7 million, up from -$116.2 million in the prior quarter.
- The five-year high for Change in Inventory was $142.6 million in Q1 2022, with the low at -$116.2 million in Q1 2026.
- The 5-year median for Change in Inventory is $47.9 million (2024), against an average of $33.2 million.
- The sharpest annual moves came in 2023 and 2026: Change in Inventory soared 630.39% in 2023, then sank 184.2% in 2026.
- Biogen's Change in Inventory stood at -$18.1 million in 2022, then jumped by 630.39% to $96.0 million in 2023, then sank by 30.83% to $66.4 million in 2024, then plunged by 55.72% to $29.4 million in 2025, then slumped by 357.48% to -$75.7 million in 2026.
- Business Quant data shows BIIB's Change in Inventory at -$75.7 million in Q2 2026, -$116.2 million in Q1 2026, and $29.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -75.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.70 Mn |
| Jun 30, 2026 | -75.70 Mn |
| Mar 31, 2026 | -116.20 Mn |
| Mar 31, 2026 | -116.20 Mn |
| Dec 31, 2025 | 29.40 Mn |
| Dec 31, 2025 | 29.40 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 89.90 Mn |
| Jun 30, 2025 | 89.90 Mn |
| Mar 31, 2025 | -62.00 Mn |
| Mar 31, 2025 | -62.00 Mn |
| Dec 31, 2024 | 66.40 Mn |
| Dec 31, 2024 | 66.40 Mn |
| Sep 30, 2024 | 19.20 Mn |
| Sep 30, 2024 | 19.20 Mn |
| Jun 30, 2024 | 110.50 Mn |
| Jun 30, 2024 | 110.50 Mn |
| Mar 31, 2024 | 77.70 Mn |
| Mar 31, 2024 | 77.70 Mn |